Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

KRW, Emary; T, Golubchik; PK, Aley; CV, Ariani; B, Angus; S, Bibi; B, Blane; D, Bonsall; P, Cicconi; S, Charlton; EA, Clutterbuck; AM, Collins; T, Cox; TC, Darton; C, Dold; AD, Douglas; CJA, Duncan; CJA, Duncan; KJ, Ewer; AL, Flaxman; SN, Faust; DM, Ferreira; S, Feng; A, Finn; PM, Folegatti; M, Fuskova; E, Galiza; AL, Goodman; CM, Green; CA, Green; M, Greenland; B, Hallis; PT, Heath; J, Hay; HC, Hill; D, Jenkin; S, Kerridge; R, Lazarus; V, Libri; PJ, Lillie; C, Ludden; NG, Marchevsky; AM, Minassian; AC, McGregor; YF, Mujadidi; DJ, Phillips; E, Plested; KM, Pollock; H, Robinson; A, Smith; R, Song; MD, Snape; RK, Sutherland; EC, Thomson; M, Toshner; DPJ, Turner; J, Vekemans; TL, Villafana; CJ, Williams; CJ, Williams; AVS, Hill; T, Lambe; SC, Gilbert; M, Voysey; MN, Ramasamy; AJ, Pollard

doi:10.1016/s0140-6736(21)00628-0

Public

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Shared by NobleBlocks on Mar 30, 2021 • 12:00 AM UTC

Authors:

Emary KRW

Golubchik T

Aley PK

Abstract

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.Methods Volunteers (aged ≥18 years) who we...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!